Accuray Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This Accuray Value Chain Analysis helps you understand how the company creates value across support and primary activities in a clear, practical framework. This page already shows a real preview of the actual analysis, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Accuray Incorporated's firm infrastructure matters because FY2025 net revenue was $458.6 million, so quality, finance, and regulatory control must stay tight across a large installed base sold to hospitals and cancer centers.
With 36.4% gross margin in FY2025, disciplined oversight also helps protect pricing, compliance, and service execution across long product cycles.
This control links engineering, manufacturing, and clinical support so Accuray Incorporated can meet global rules and keep systems running in the field.
Human Resource Management
Accuray Incorporated relies on specialized engineers, software developers, clinical applications specialists, sales staff, and field service technicians to support its radiation oncology systems. Hiring and keeping talent with precision-medical-device and oncology experience helps protect product quality, speed clinical support, and build customer trust after installation. In fiscal 2025, this people-heavy support base remained central to uptime, service response, and software reliability.
Technology Development
Technology development is core to Accuray Incorporated because CyberKnife and TomoTherapy stand out on software, imaging guidance, and precise dose delivery. In fiscal 2025, Accuray Incorporated reported about $457 million in revenue and spent roughly $42 million on research and development, showing steady investment in planning, automation, and clinical performance. That spend helps defend its niche in high-acuity oncology by improving treatment speed, accuracy, and workflow.
Procurement
Accuray Incorporated must source precision parts, electronics, imaging subsystems, and contract manufacturing with tight supplier quality checks. In FY2025, that matters because one bad component can raise rework, delay installs, and hurt uptime in high-value radiation systems. Smart procurement reduces supply risk, protects reliability, and helps keep the cost base lean in complex capital equipment.
Accuray's FY2025 Support Engine Kept Precision, Compliance and Uptime on Track
Accuray Incorporated's support activities in FY2025 were built to protect precision, compliance, and uptime across a $458.6 million revenue base.
Firm infrastructure and procurement helped hold gross margin at 36.4%, while R&D of about $42 million kept CyberKnife and TomoTherapy software and imaging features current.
Specialized talent and field support stayed central to service speed, install quality, and reliable system performance.
| Support activity | FY2025 data |
|---|---|
| Firm infrastructure | $458.6M revenue; 36.4% gross margin |
| Technology development | ~$42M R&D |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Accuray Incorporated sources specialized components, electronics, imaging hardware, and software inputs from a tight supplier base, so inbound quality checks are critical. In fiscal 2025, Accuray Incorporated reported revenue of about $459 million, which shows how even small supply delays can hit assembly flow and hospital delivery timing. Careful receiving, traceability, and defect control help protect validation steps and keep high-value systems moving on schedule.
Operations
Accuray's Operations turn engineering into clinic-ready CyberKnife and TomoTherapy systems through assembly, software integration, testing, calibration, and final validation. In FY2025, that work supported 2 core platforms, so even small defects can ripple into safety, uptime, and margins. Tight quality control matters because it protects performance before systems reach hospitals and treatment centers.
Outbound Logistics
Accuray Incorporated's outbound logistics is built around moving high-value, room-scale radiation systems to hospitals and cancer centers, not boxed medical goods. In fiscal 2025, Accuray reported about $458 million in revenue, and each system shipment needs precise scheduling because the install site, shielding, power, and IT links must be ready before delivery.
This makes customs work, freight handling, and white-glove installation part of the value chain, and delays can stall revenue recognition on capital equipment deals. The same logistics flow also supports global service coverage for a base of more than 1,000 installed systems worldwide.
Marketing and Sales
Accuray Incorporated's marketing and sales depend on direct ties with radiation oncologists, hospital leaders, and buying teams, because its systems are sold on clinical proof, workflow fit, and economic value. In fiscal 2025, Accuray Incorporated reported revenue of about $458 million, and that scale reflects a sales motion built around long hospital cycles and high-cost capital purchases. Its two platform families, CyberKnife and Radixact, let Accuray Incorporated target different treatment needs and support value-based selling in oncology centers.
Service
Accuray Incorporated's service activity covers installation support, operator training, preventive maintenance, spare parts, and software upgrades. In fiscal 2025, with revenue near $460 million, this work mattered because Accuray Incorporated systems stay in place for years, so high uptime supports customer retention and recurring service sales after the initial sale.
Accuray FY2025: $458M Revenue, 1,000+ Systems, Two Core Platforms
Accuray Incorporated's primary activities in FY2025 centered on building, selling, and supporting CyberKnife and Radixact systems, with revenue of about $458 million.
Operations and outbound logistics stayed critical because these are large, site-ready cancer systems that need assembly, calibration, shipping, and installation coordination.
Marketing, sales, and service were built around long hospital cycles, clinical proof, and recurring maintenance for more than 1,000 installed systems worldwide.
| FY2025 metric | Value |
|---|---|
| Revenue | $458 million |
| Installed base | 1,000+ systems |
| Core platforms | 2 |
Full Version Awaits
Accuray Reference Sources
This is the actual Accuray Value Chain Analysis document you'll receive after purchase – no surprises, just the full professional version. The preview below is taken directly from the complete report, so what you see here is exactly what you'll get. Purchase unlocks the full, detailed document immediately.
Frequently Asked Questions
Accuray Incorporated's value chain is anchored by technology development and regulated operations. The company's 2 flagship platforms, CyberKnife and TomoTherapy, must connect cleanly to 5 downstream activities, from inbound logistics to service. That mix makes the front end of the chain more important than scale alone because product performance drives hospital adoption.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.